logo
Telix Adds Lead-212 Isotope Production Capability

Telix Adds Lead-212 Isotope Production Capability

Yahoo12-03-2025

MELBOURNE, Australia and INDIANAPOLIS, March 13, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that it has developed and validated a breakthrough generator technology for the production of lead-212 (212Pb) and successfully completed first production.
The new generator technology, developed internally by Telix's IsoTherapeutics team, produces 212Pb via a sealed Thorium-228 (228Th) source, and significantly increases the amount of radioactivity, yield and shelf life compared to currently available 212Pb generators. The fully automated, high-output generators have a small, single hot cell footprint and produce sufficient 212Pb elution for up to 60 clinical doses, with the potential to further scale. The production footprint has been designed to be deployed throughout Telix's (and select partner) manufacturing and distribution networks, including the recently acquired RLS Radiopharmacies network. This development builds on Telix's extensive experience with developing generator-based radiopharmaceutical products.
The novel technology opens new opportunities for the development of alpha-emitting radiopharmaceuticals for use in Telix's next-generation therapeutics pipeline. Lead-212 is a promising isotope for Targeted Alpha Therapy (TAT) but its relatively short half-life (10.6 hours, compared with 9.9 days for actinium-225, 225Ac) and lack of production scale has limited commercial potential. The alpha-emitting profile of 212Pb also has practical synergies with engineered antibodies being developed using Telix's newly acquired discovery platform[1], with pharmacology and clearance organ characteristics that are well suited to its short half-life.
Chad Watkins, General Manager, Isotope Strategy, Telix, said, "A lead-212 generator that produces minimal waste and fits within the current radiopharmacy footprint is a step change in the production of this alpha emitting therapeutic radioisotope. It creates the potential for commercial scale lead-212 isotope production that wasn't possible before and opens up new pathways for matching this promising alpha isotope with a range of targeting agents."
About Telix Pharmaceuticals Limited
Telix is a biopharmaceutical company focused on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals and associated medical technologies. Telix is headquartered in Melbourne, Australia, with international operations in the United States, Canada, Europe (Belgium and Switzerland), and Japan. Telix is developing a portfolio of clinical and commercial stage products that aims to address significant unmet medical needs in oncology and rare diseases. ARTMS, IsoTherapeutics, Lightpoint, Optimal Tracers and RLS are Telix Group companies. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (Nasdaq: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and SEC filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
Telix Investor Relations
Ms. Kyahn WilliamsonTelix Pharmaceuticals LimitedSVP Investor Relations and Corporate CommunicationsEmail: kyahn.williamson@telixpharma.com
Legal Notices
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "believe", "outlook", "forecast" and "guidance", or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix's good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix's business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix's business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix's preclinical and clinical trials, and Telix's research and development programs; Telix's ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix's product candidates, manufacturing activities and product marketing activities; Telix's sales, marketing and distribution and manufacturing capabilities and strategies; the commercialisation of Telix's product candidates, if or when they have been approved; Telix's ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix's expenses, future revenues and capital requirements; Telix's financial performance; developments relating to Telix's competitors and industry; and the pricing and reimbursement of Telix's product candidates, if and after they have been approved. Telix's actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
©2025 Telix Pharmaceuticals Limited. The Telix Pharmaceuticals®, Telix Group company, and Telix product names and logos are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved. Trademark registration status may vary from country to country.
[1] Telix ASX disclosure 31 January 2025.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/telix-adds-lead-212-isotope-production-capability-302400465.html
SOURCE Telix Pharmaceuticals Limited

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AIDCF Releases Landmark Report Highlighting Job Loss Crisis and Urges for Urgent Reforms in India's Cable TV Sector
AIDCF Releases Landmark Report Highlighting Job Loss Crisis and Urges for Urgent Reforms in India's Cable TV Sector

Business Upturn

time19 minutes ago

  • Business Upturn

AIDCF Releases Landmark Report Highlighting Job Loss Crisis and Urges for Urgent Reforms in India's Cable TV Sector

NEW DELHI , June 10, 2025 /PRNewswire/ — All India Digital Cable Federation today launched a landmark study titled ' State of Cable TV Distribution in India ' . Developed in collaboration with EY India, the report offers critical insights into the challenges, evolution, and future of India's cable television ecosystem. It brings together extensive field data and sectoral analysis to present a comprehensive view of the Cable TV distribution landscape. Based on inputs from over 28,000 Local Cable Operators (LCOs) across India , the report highlights a sharp decline in cable TV subscriptions—driven by rising channel costs and competition from unregulated platforms—which, in turn, has led to a significant employment crisis. Key findings of the report include: The workforce of surveyed LCOs declined by 31% since 2018 , with a reported loss of 37,835 jobs . When extrapolated nationally, the estimated job loss ranges between 1.14 lakh and 1.95 lakh . , with a reported loss of . When extrapolated nationally, the estimated job loss ranges between . Pay TV households declined by 40 million , from 151 million in 2018 to 111 million in 2024. , from 151 million in 2018 to 111 million in 2024. 93% LCOs reported a decline in their subscriber base since 2018; LCOs reported a since 2018; 49% of LCOs reported a drop in their monthly income . of LCOs reported a . 35% reported subscriber loss of over 40%. Key reforms suggested by the report include: Enabling of level-playing field across all content distribution mediums across all content distribution mediums Permitting differential pay TV pricing for different territories based on ability to pay for different territories based on ability to pay Activating over 20 million inactive STBs in India Restrict or limit the provision of live or slightly delayed transmission of pay TV content for free on other platforms Take a unified stand against piracy Mr. Sanjiv Shankar, Additional Secretary, Ministry of Consumer Affairs; Former Joint Secretary, Ministry of Information and Broadcasting, shared his remarks: 'This report is truly one of its kind—comprehensive, data-driven, and grounded in the realities of the ground-level cable ecosystem. It brings into focus the structural shifts and challenges within the sector, and provides a valuable evidence base for future policy-making.' Mr. S.N. Sharma, CEO of DEN Networks Limited and President of AIDCF, expressed his enthusiasm about the report: 'This report is perhaps the most comprehensive bottom-up view of the Pay TV distribution sector in recent times.' 'The report presents not just statistics but stories of lost livelihood impacting families and entrepreneurship, and they need be heard across the broadcasting ecosystem.' 'While the report presents conservative estimates, the situation is even more grave. When factoring in the closure of approximately 900 MSOs and 72,000 LCOs over the past six years, the total cumulative job loss is estimated to exceed 5.77 lakh.' 'We urge all stakeholders — including broadcasters, regulators, and our parent ministry — to use the report as a base to bring practical reforms and support the cable TV industry to thrive once again.' Mr. Ashish Pherwani, Partner, Media & Entertainment Sector, EY India, remarked that: 'This is a first-of-its-kind report that captures the true pulse of the cable TV distribution network in India . Its scale, depth of field data, and insight into last-mile realities make it a valuable resource for both industry and policymakers alike.' The report was released during a special event held at Shangri-La Eros, New Delhi , where senior policymakers, industry leaders, and key stakeholders from across the broadcasting and media landscape came together to deliberate on the findings and implications of this industry-first report. The report can be accessed from AIDCF's official website or by clicking on this link. About All India Digital Cable Federation (AIDCF) All India Digital Cable Federation is the apex body for Digital Multi-System Operators (MSOs) in India . AIDCF is the official voice for the Indian digital cable TV industry and works towards the overall growth of the sector. AIDCF has consistently championed the interests of the cable TV distribution industry and remains committed to promoting a fair, competitive, and sustainable broadcasting ecosystem. The members of the federation have a combined market share of > 65%. Members of AIDCF includes Asianet Satellite Communications Limited, DEN Networks Limited, Fastway Transmission Private Limited, GTPL Hathway Private Limited, Hathway Cable & Datacom Limited, Kerala Communicators Cable Limited, NXT Digital, SITI Cable Network Limited and UCN Cable Network Private Limited. Photo: View original content to download multimedia: Disclaimer: The above press release comes to you under an arrangement with PR Newswire. Business Upturn takes no editorial responsibility for the same.

Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025
Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025

Yahoo

time22 minutes ago

  • Yahoo

Caliway to Present First Preclinical Data on CBL-514 for GLP-1 Weight Rebound Management at BIO 2025

Caliway to deliver a corporate presentation on June 17 at the BIO International Convention 2025, the world's largest biotech industry event. For the first time at an international conference, Caliway will share preclinical results on CBL-514's potential new indication: combined with GLP-1 therapies to prevent post-treatment weight rebound. NEW TAIPEI CITY, June 10, 2025 /PRNewswire/ -- Caliway Biopharmaceuticals (TWSE: 6919) announced today its participation in the 2025 BIO International Convention, to be held from June 16 to 19 in Boston, U.S.A. Caliway's Vice President, April Yuan, will deliver an oral presentation on June 17, highlighting the company's latest progress in R&D and pipeline development. The presentation will cover recent updates on CBL-514, first-in-class injectable drug candidate for large-area, site-specific fat reduction, including its development across multiple indications—subcutaneous fat reduction, cellulite, and Dercum's disease. For the first time at an international conference, Caliway will also share preclinical data on a potential new indication: weight rebound management through a combination therapy with GLP-1 receptor agonists. As GLP-1 receptor agonists gain widespread use globally, post-discontinuation weight rebound has become a significant, yet unmet clinical concern. According to published studies, only 10% of patients are able to maintain weight loss after stopping GLP-1 treatment. Based on Caliway's preclinical data, co-administration of CBL-514 with GLP-1 significantly reduced post-discontinuation body weight regain and fat replenishment rate — suggesting that CBL-514 may help maintain weight loss outcomes after GLP-1 therapy. CBL-514 works by directly targeting the root cause—subcutaneous fat—through selective induction of adipocyte apoptosis. It may serve as a complementary combination therapy to GLP-1s, pairing systemic weight loss with precise body contouring. Caliway plans to submit a Phase 2 IND application to the U.S. FDA for this new indication in Q4 2025. "We believe post-weight-loss weight rebound is a promising unmet market need," said Vivian Ling, CEO of Caliway. "CBL-514 has the potential to serve as a complementary combination therapy with GLP-1 treatments — with GLP-1s driving weight reduction, and CBL-514 reshaping and maintaining outcomes through localized fat reduction, enhancing the overall treatment impact and long-term value." The BIO International Convention is the world's largest and most influential biotechnology event, attracting over 20,000 professionals and 5,000 companies from 80+ countries. It serves as a global platform for business development, innovation exchange, and investment. Caliway Presentation at BIO 2025: Date & Time: Tuesday, June 17, 2025 | 11:45 AM – 12:00 PM (EDT) Location: Room 154 | Boston Convention & Exhibition Center Speaker: April Yuan, VP, Caliway Biopharmaceuticals Session Info: About CBL-514CBL-514, a 505(b)(1) and first-in-class small-molecule drug developed by Caliway, is the world's first injectable lipolysis drug that induces adipocyte apoptosis to reduce subcutaneous fat in targeted areas without causing any systemic side effects on the central nervous system, cardiovascular system, and respiratory system. As of May 2025, 10 clinical trials with a total of 520 subjects have been completed with all efficacy and safety endpoints met. Caliway is currently investigating multiple indications for CBL-514, including non-surgical fat reduction, moderate-to-severe cellulite, and weight rebound management through a combination therapy with GLP-1-based treatments. CBL-514D, the same active pharmaceutical ingredients (APIs) but under different formulation, is being studied for additional indications such as Dercum's disease and more. About Caliway BiopharmaceuticalsCaliway Biopharmaceuticals (Caliway) is a clinical-stage biopharmaceutical company driven to breakthrough drug discovery of novel small-molecule therapeutics. Listed on the Taiwan Exchange (TWSE-6919), Caliway aims to become an innovative pharmaceutical leader in aesthetic medicine and other diseases. For more information, please visit: DisclaimerThis article and related information on this site contain forward-looking statements. The forward-looking information requires the Company to make numerous assumptions and is subject to inherent risks, uncertainties, and other factors that are beyond the control of the Company which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. The Company undertakes no obligation to timely inform, update, or revise the information on this site if circumstances should change. View original content to download multimedia: SOURCE Caliway Biopharmaceuticals Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Nordic Breakthrough for Unlimited Fossil-Free Energy - NOVATRON 1 Officially Inaugurated
Nordic Breakthrough for Unlimited Fossil-Free Energy - NOVATRON 1 Officially Inaugurated

Yahoo

time22 minutes ago

  • Yahoo

Nordic Breakthrough for Unlimited Fossil-Free Energy - NOVATRON 1 Officially Inaugurated

STOCKHOLM, June 10, 2025 /PRNewswire/ -- On June 9, NOVATRON 1 was officially inaugurated at the Royal Institute of Technology (KTH) in Stockholm - the EU's first private, fully integrated fusion plasma system. The event marks a historic milestone for Sweden and the Nordic region in the development of commercial fusion energy. With Novatron Fusion Group (NFG) leading the charge, the Nordics are uniquely positioned to shape the future of energy through innovation, collaboration, and technological leadership. Fusion technology has the potential to address some of the most pressing global challenges of our time - from climate change to growing energy demand. Realizing this potential requires cross-sector collaboration between industry, academia, and policymakers. NFG is actively working to establish a strong Nordic fusion cluster and position the region as a driving force in the transition to a sustainable energy future. The inauguration brought together representatives from across the Nordic innovation ecosystem - including industry, academia, and government - with nearly all parties from the Swedish Parliament's Energy Committee in attendance. The broad participation underscores the strong support for fusion's role in the future energy mix. - The inauguration of NOVATRON 1 is a milestone - not only for our company but for the entire Nordic region. We're showing that it's possible to take concrete steps toward commercial fusion energy here and now. Our vision is that the Nordics will realize fusion, and today's event is powerful proof that we're on the right path, says Peter Roos, CEO of Novatron Fusion Group. Fusion energy - often referred to as "The Holy Grail of Energy" - has the potential to deliver continuous, safe, and fossil-free baseload power. As one of Europe's leading fusion companies, NFG is not only advancing fusion energy in the Nordics but also helping to strengthen Europe's energy resilience. At a time when G7 nations are highlighting fusion as a strategic solution to the climate crisis and energy security, European independence and cooperation in the energy sector are more important than ever. - NFG's groundbreaking technology is a vital contribution from Sweden to Europe's energy independence and climate transition, says Professor Christer Fuglesang, KTH Space Center. The NOVATRON concept is based on a unique design by innovator Jan Jäderberg and has been developed by a world-class team of physicists, engineers, and researchers. The technology addresses one of the biggest challenges in commercial fusion: stable and continuous confinement of fusion plasma without interruptions in energy production. This is described in more detail in a scientific article published last week, which highlights, among other things, NOVATRON's potential to achieve groundbreaking energy exchange values. With this promising concept, NFG aims to provide cost-effective and globally scalable baseload power to the grid within the next decade. During the inauguration, visitors witnessed a live plasma experiment in the prototype facility - the Nordic region's first step toward a commercial fusion reactor and a fossil-free society. - We believe that NFG has a game changing formula and as an owner with a long-term mindset, we're excited to help accelerate the work towards limitless fossil-free energy, says Henrikki Talvitie, CEO of St1. For more information, please contact:Jeanette MattssonMarketing and Communications Director, Novatron Fusion GroupEmail: Phone: +46 76 051 75 16 This information was brought to you by Cision The following files are available for download: NFG press release Peter Roos, CEO of NFG Prof. Christer Fuglesang Swedish Parliament's Energy Committee and CEO of NFG View original content: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store